Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
KMT Hepatech is expanding its services with the PXB-Mouse – a humanized liver chimeric mouse model for drug discovery and development – following a strategic investment from PhoenixBio late last year.
It is an “exciting time in drug discovery,” says Charles River CSO as the company expands its CRISPR/Cas9 service offering with a license from ERS Genomics.
AMRI’s SSCI has announced the availability of in vitro bioequivalence testing services, as more products entering the market require laboratory-based testing.
EAG Laboratories has added dermal absorption studies to its GLP-compliant testing services suite, as part of the company’s plan to continue expanding its capabilities.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
Sensors, computer vision, machine learning, and cloud computing are enabling preclinical researchers to conduct higher quality studies in a shorter period of time.
Cyprotex has expanded its toxicology offering with a new in silico technology it claims will reduce preclinical costs and cut the number of animal studies required.
Preclinical CRO Agilux has increased capacity at its research facility in Massachusetts, US, citing customer desire for faster in vivo studies as the driver for the investment.
Caliper Life sciences has entered into a definitive merger agreement with Cambridge Research & Instrumentation (CRi) to boost its discovery biomarker and personalised medicine development offering.
Precos is aiming to accelerate growth of its attrition-reducing preclinical oncology screening services by naming a co-founder of ClinPhone as chairman.
A team of US scientists have used typically discarded body parts to
create a 'joint in a test tube', which can be used to test
arthritis drugs instead of using animals.
Specialty chemicals maker Rohm and Haas has designed new equipments
for its drug dissolution testing that it claims can reliably
predict the release of oral drugs in vivo, and therefore
potentially reduce the amount of animal testing.
Johnson & Johnson Pharmaceutical Research and Development
(J&JPRD) and the Hurel Corporation have entered into a joint
scientific collaboration to develop microfluidic, technology, with
a view to launching the world's...
A US start-up company specialising in biomaterials, 3DMatrix, has
developed a synthetic scaffold product that can be used to create
self-assembling, microscale environments to encourage the growth of
cells in culture.
